Cefixime
Cefixime, Suprax (cefixime) is a small molecule pharmaceutical. Cefixime was first approved as Suprax on 1989-04-28. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, bronchitis, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Suprax (generic drugs available since 2007-04-10)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefixime
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUPRAX | Lupin Research | N-202091 RX | 2013-02-20 | 1 products, RLD, RS |
| SUPRAX | Lupin Research | N-203195 RX | 2012-06-01 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefixime | ANDA | 2023-12-05 |
| cefixime 400 mg ud | ANDA | 2023-01-13 |
| suprax | ANDA, New Drug Application | 2023-12-15 |
Indications
FDA
EMA
Show 5 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cefixime, Suprax, Lupin Ltd | |||
| 9233112 | 2028-12-14 | DP | U-1676 |
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD08: Cefixime
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA15: Cefixime and ornidazole
— J01RA16: Cefixime and azithromycin
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gonorrhea | D006069 | DOID_7551 | A54 | 2 | 2 | — | 2 | 1 | 7 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | 2 | 1 | 4 |
| Chlamydia infections | D002690 | EFO_0007205 | A74.9 | — | 1 | — | 1 | 1 | 3 |
| Typhoid fever | D014435 | EFO_0006789 | A01.0 | — | — | — | 2 | — | 2 |
| Neisseria gonorrhoeae | D009344 | NCBITaxon_485 | — | — | — | — | 1 | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | — | 1 | — | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | — | 1 | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 1 | — | 1 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syphilis | D013587 | EFO_0007504 | A53.9 | 1 | 2 | 1 | — | — | 3 |
| Uterine cervicitis | D002575 | HP_0030160 | N72 | — | — | 1 | — | — | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | — | 1 | — | — | 1 |
| Liver abscess | D008100 | HP_0100523 | K75.0 | — | — | 1 | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
| Vesico-ureteral reflux | D014718 | EFO_0007536 | N13.7 | — | — | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | — | 1 | 1 | — | — | 1 |
| Hiv | D006678 | — | O98.7 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 3 | 1 | — | — | — | 4 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | — | — | — | — | 4 |
| Bacterial infections | D001424 | — | A49 | 2 | — | — | — | 1 | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 1 | — | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | — | — | — | — | 1 |
| Hepatoblastoma | D018197 | — | C22.2 | 1 | — | — | — | — | 1 |
| Wilms tumor | D009396 | EFO_0000212 | — | 1 | — | — | — | — | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy-induced febrile neutropenia | D064146 | — | — | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Laboratory infection | D007757 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefixime |
| INN | cefixime |
| Description | Cefixime is a third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections. It has a role as an antibacterial drug and a drug allergen. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1 |
Identifiers
| PDB | — |
| CAS-ID | 79350-37-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1541 |
| ChEBI ID | 472657 |
| PubChem CID | 5362065 |
| DrugBank | DB00671 |
| UNII ID | XZ7BG04GJX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cefixime
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,173 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use